fbpx

Treatment Locator

Monoclonal Antibody Therapy

Monoclonal antibody treatments can prevent severe illness, hospitalization and death in high-risk patients who have contracted or been exposed to COVID-19. The antibodies help the immune system recognize and respond effectively to the virus. According to the treatment guidelines, they should be administered as soon as possible after diagnosis.

  • Treatment is free and vaccination status does not matter. If you are 12 years and older and are at high risk for severe illness due to COVID-19, you are eligible for this treatment.
  • There is currently a standing order in Florida signed by the State Surgeon General that allows patients to receive this treatment without a prescription or referral if administered by an eligible health care provider.
  • In clinical trials, monoclonal antibody treatment showed a 70% reduction in hospitalization and death.
  • For high-risk patients who have been exposed to someone with COVID19, Regeneron can give you temporary immunity to decrease your odds of catching the infection by over 80%.

For more information, call the Florida Department of Health Monoclonal Antibody Treatment Support Line: 850-344-9637.

 

AstraZeneca EvuSheld: Preventative Monoclonal Antibody Therapy

On December 8, 2021, the U.S. Food and Drug Administration issued an emergency use authorization for AstraZeneca’s Evusheld for the pre-exposure prophylaxis (prevention) of COVID-19 in certain populations 12 years of age and older.

AstraZeneca’s Evusheld is authorized for:

  • Individuals who are moderately to severely immunocompromised and may not mount an adequate immune response to COVID-19 vaccines.
  • Individuals with a history of severe adverse reactions to COVID-19 vaccines and/or components of the vaccines.

The Florida Department of Health will continue to update the public as this therapy is delivered from the federal government and becomes available at the providers below. Eligible individuals should contact their health care provider if interested in this pre-exposure therapy.

Find a COVID-19 Treatment Location

Location Pin Key
Monoclonal Antibody Therapy
AstraZeneca EvuSheld: Preventative Monoclonal Antibody Therapy
Paxlovid and Molnupiravir Oral Antiviral

Frequently Asked Questions

AstraZeneca’s Evusheld is a preventative monoclonal antibody therapy. It is authorized for:

  • Individuals who are moderately to severely immunocompromised and may not mount an adequate immune response to COVID-19 vaccines.
  • Individuals with a history of severe adverse reactions to COVID-19 vaccines and/or components of the vaccines.
Eligible individuals should contact their health care provider if interested in this pre-exposure therapy.

Individuals eligible for AstraZeneca’s Evusheld should contact their health care provider if interested in this pre-exposure therapy.

There is currently a standing order in Florida signed by the State Surgeon General that allows patients to receive all other monoclonal antibody treatments without a prescription or referral if administered by an eligible health care provider. Such referrals are not required at these State of Florida monoclonal antibody treatment sites.

At the direction of Governor DeSantis, the Florida Department of Health and Florida Division of Emergency Management are working together to deploy mobile and stationary monoclonal antibody therapy treatment sites. Click here to find a monoclonal antibody treatment site.

Individuals eligible for AstraZeneca’s Evusheld should contact their health care provider if interested in this pre-exposure therapy.

There is no cost for monoclonal antibody treatment. No one will be denied services due to inability to pay for administrative cost at State of Florida sites. However, insurance can be billed if available.

AstraZeneca’s Evusheld is a preventative monoclonal antibody therapy. Eligible individuals should contact their health care provider if interested in this pre-exposure therapy.

There is not a time limit to receive other monoclonal antibody treatments, however it must be delivered prior to the occurrence of severe illness. This treatment is available to all eligible people, regardless of vaccination status.

High-risk patients should get treatment as quickly as possible after testing positive for COVID- 19. Examples of medical conditions that may pose a higher risk for severe illness and could potentially benefit from this treatment include, but are not limited to:

  • Older age (65 years of age and older)
  • Individuals overweight
  • Chronic kidney disease
  • Diabetes
  • Pregnancy
  • Immunosuppressive disease or treatments
  • Cardiovascular disease
  • Chronic lung diseases
  • Sickle cell disease
  • Neurodevelopmental disorders such as cerebral palsy
  • Having medical-related technological dependence such as tracheostomy or gastrostomy